Annual CFO
-$33.53 M
-$14.82 M-79.17%
December 31, 2023
Summary
- As of February 7, 2025, ZVRA annual cash flow from operations is -$33.53 million, with the most recent change of -$14.82 million (-79.17%) on December 31, 2023.
- During the last 3 years, ZVRA annual CFO has fallen by -$31.60 million (-1629.50%).
- ZVRA annual CFO is now -421.25% below its all-time high of $10.44 million, reached on December 31, 2021.
Performance
ZVRA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$18.14 M
+$968.00 K+5.07%
September 30, 2024
Summary
- As of February 7, 2025, ZVRA quarterly cash flow from operations is -$18.14 million, with the most recent change of +$968.00 thousand (+5.07%) on September 30, 2024.
- Over the past year, ZVRA quarterly CFO has dropped by -$1.98 million (-12.27%).
- ZVRA quarterly CFO is now -209.26% below its all-time high of $16.60 million, reached on June 1, 2021.
Performance
ZVRA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$69.57 M
-$13.51 M-24.10%
September 30, 2024
Summary
- As of February 7, 2025, ZVRA TTM cash flow from operations is -$69.57 million, with the most recent change of -$13.51 million (-24.10%) on September 30, 2024.
- Over the past year, ZVRA TTM CFO has dropped by -$36.04 million (-107.46%).
- ZVRA TTM CFO is now -684.30% below its all-time high of $11.91 million, reached on June 1, 2021.
Performance
ZVRA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ZVRA Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -79.2% | -12.3% | -107.5% |
| 3 y3 years | -1629.5% | -12.3% | -107.5% |
| 5 y5 years | +38.1% | -12.3% | -107.5% |
ZVRA Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -421.3% | at low | -2039.3% | +5.1% | -766.5% | at low |
| 5 y | 5-year | -421.3% | at low | -209.3% | +5.1% | -684.3% | at low |
| alltime | all time | -421.3% | +38.1% | -209.3% | +5.1% | -684.3% | at low |
Zevra Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$18.14 M(-5.1%) | -$69.57 M(+24.1%) |
| Jun 2024 | - | -$19.11 M(+18.2%) | -$56.06 M(+22.8%) |
| Mar 2024 | - | -$16.16 M(+0.0%) | -$45.66 M(+36.1%) |
| Dec 2023 | -$33.53 M(+79.2%) | -$16.16 M(+249.1%) | -$33.53 M(+53.6%) |
| Sep 2023 | - | -$4.63 M(-46.8%) | -$21.84 M(-8.3%) |
| Jun 2023 | - | -$8.70 M(+115.2%) | -$23.81 M(+23.9%) |
| Mar 2023 | - | -$4.04 M(-9.3%) | -$19.21 M(+2.6%) |
| Dec 2022 | -$18.72 M(-279.3%) | -$4.46 M(-32.4%) | -$18.72 M(+23.9%) |
| Sep 2022 | - | -$6.60 M(+60.8%) | -$15.10 M(+34.4%) |
| Jun 2022 | - | -$4.10 M(+15.5%) | -$11.23 M(-218.6%) |
| Mar 2022 | - | -$3.55 M(+319.0%) | $9.47 M(-9.3%) |
| Dec 2021 | $10.44 M(-638.4%) | - | - |
| Dec 2021 | - | -$848.00 K(-68.9%) | $10.44 M(+2.1%) |
| Sep 2021 | - | -$2.73 M(-116.4%) | $10.23 M(-14.1%) |
| Jun 2021 | - | $16.60 M(-742.0%) | $11.91 M(-575.7%) |
| Mar 2021 | - | -$2.59 M(+144.2%) | -$2.50 M(+29.1%) |
| Dec 2020 | -$1.94 M(-91.8%) | -$1.06 M(+0.8%) | -$1.94 M(-51.3%) |
| Sep 2020 | - | -$1.05 M(-147.9%) | -$3.98 M(-22.8%) |
| Jun 2020 | - | $2.19 M(-208.5%) | -$5.16 M(-64.9%) |
| Mar 2020 | - | -$2.02 M(-34.7%) | -$14.69 M(-38.1%) |
| Dec 2019 | -$23.74 M | -$3.10 M(+39.0%) | -$23.74 M(-33.4%) |
| Sep 2019 | - | -$2.23 M(-69.6%) | -$35.64 M(-27.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2019 | - | -$7.34 M(-33.6%) | -$49.36 M(-3.5%) |
| Mar 2019 | - | -$11.07 M(-26.2%) | -$51.17 M(-5.6%) |
| Dec 2018 | -$54.20 M(+63.8%) | -$15.00 M(-6.0%) | -$54.20 M(+17.5%) |
| Sep 2018 | - | -$15.95 M(+74.3%) | -$46.14 M(+14.3%) |
| Jun 2018 | - | -$9.15 M(-35.1%) | -$40.36 M(+7.1%) |
| Mar 2018 | - | -$14.10 M(+103.3%) | -$37.68 M(+13.8%) |
| Dec 2017 | -$33.10 M(+11.2%) | -$6.94 M(-31.8%) | -$33.10 M(-6.8%) |
| Sep 2017 | - | -$10.17 M(+57.1%) | -$35.52 M(+5.6%) |
| Jun 2017 | - | -$6.47 M(-32.0%) | -$33.63 M(-5.1%) |
| Mar 2017 | - | -$9.52 M(+1.7%) | -$35.43 M(+19.0%) |
| Dec 2016 | -$29.77 M(+46.9%) | -$9.36 M(+13.1%) | -$29.77 M(+11.0%) |
| Sep 2016 | - | -$8.27 M(-0.0%) | -$26.82 M(+15.8%) |
| Jun 2016 | - | -$8.27 M(+114.1%) | -$23.15 M(+15.0%) |
| Mar 2016 | - | -$3.87 M(-39.6%) | -$20.13 M(-0.7%) |
| Dec 2015 | -$20.27 M(+38.2%) | -$6.40 M(+38.9%) | -$20.27 M(-2.7%) |
| Sep 2015 | - | -$4.61 M(-12.3%) | -$20.83 M(+3.6%) |
| Jun 2015 | - | -$5.25 M(+31.4%) | -$20.10 M(+13.1%) |
| Mar 2015 | - | -$4.00 M(-42.6%) | -$17.78 M(+21.2%) |
| Dec 2014 | -$14.67 M(+239.1%) | -$6.96 M(+79.2%) | -$14.67 M(+90.3%) |
| Sep 2014 | - | -$3.89 M(+32.4%) | -$7.71 M(+101.7%) |
| Jun 2014 | - | -$2.93 M(+230.4%) | -$3.82 M(+330.4%) |
| Mar 2014 | - | -$888.00 K | -$888.00 K |
| Dec 2013 | -$4.33 M | - | - |
FAQ
- What is Zevra Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Zevra Therapeutics?
- What is Zevra Therapeutics annual CFO year-on-year change?
- What is Zevra Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Zevra Therapeutics?
- What is Zevra Therapeutics quarterly CFO year-on-year change?
- What is Zevra Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Zevra Therapeutics?
- What is Zevra Therapeutics TTM CFO year-on-year change?
What is Zevra Therapeutics annual cash flow from operations?
The current annual CFO of ZVRA is -$33.53 M
What is the all time high annual CFO for Zevra Therapeutics?
Zevra Therapeutics all-time high annual cash flow from operations is $10.44 M
What is Zevra Therapeutics annual CFO year-on-year change?
Over the past year, ZVRA annual cash flow from operations has changed by -$14.82 M (-79.17%)
What is Zevra Therapeutics quarterly cash flow from operations?
The current quarterly CFO of ZVRA is -$18.14 M
What is the all time high quarterly CFO for Zevra Therapeutics?
Zevra Therapeutics all-time high quarterly cash flow from operations is $16.60 M
What is Zevra Therapeutics quarterly CFO year-on-year change?
Over the past year, ZVRA quarterly cash flow from operations has changed by -$1.98 M (-12.27%)
What is Zevra Therapeutics TTM cash flow from operations?
The current TTM CFO of ZVRA is -$69.57 M
What is the all time high TTM CFO for Zevra Therapeutics?
Zevra Therapeutics all-time high TTM cash flow from operations is $11.91 M
What is Zevra Therapeutics TTM CFO year-on-year change?
Over the past year, ZVRA TTM cash flow from operations has changed by -$36.04 M (-107.46%)